Departure of Chief Financial Officer

Celadon Pharmaceuticals PLC

30 September 2024

 

Celadon Pharmaceuticals Plc

("Celadon", the "Group" or the "Company")

Departure of Chief Financial Officer

London, 30 September 2024 - The Board of Celadon Pharmaceuticals Plc (AIM: CEL) announces that Mr Jonathan Turner, Chief Financial Officer, will leave his position on the Board on 27 December 2024.

The Board would like to express its thanks and gratitude to Mr Turner for his contribution to the Company and wishes him well in his future endeavours.

The Company will be starting the search for Mr Turner's successor imminently and will provide a further update when a new candidate has been appointed.

Enquiries:

Celadon Pharmaceuticals Plc
James Short Jonathan Turner	Via Sodali & Co
Canaccord Genuity Limited (Nominated Adviser and Broker)
Bobbie Hilliam / Andrew Potts	[phone]
Global Investment Strategy UK Limited (Joint Broker) James Sheehan	[phone]
Sodali & Co
Elly Williamson / Sam Austrums / Nick Johnson	[phone]

About Celadon Pharmaceuticals Plc

Celadon Pharmaceuticals Plc is a UK-based pharmaceutical company focused on the development, production and sale of breakthrough cannabis-based medicines. Its primary focus is on improving quality of life for chronic pain sufferers, as well as exploring the potential of cannabis-based medicines for other conditions such as autism. Its 100,000 sq. ft UK facility is EU-GMP approved and comprises indoor hydroponic cultivation, proprietary GMP extraction and an analytical and R&D laboratory. Celadon's Home Office licence allows for the commercial supply of its pharmaceutical-grade cannabis product. The Group owns an approved clinical trial using cannabis-based medicinal products to treat chronic pain in the UK. Celadon also has a minority interest in early-stage biopharma Kingdom Therapeutics, which is developing a licensed cannabinoid medicine to treat children with Autism Spectrum Disorder.

For further information please visit our website www.celadonpharma.com

This announcement contains inside information for the purposes of article 7 of the Market Abuse Regulation (EU) 596/2014 as amended by regulation 11 of the Market Abuse (Amendment) (EU Exit) Regulations 2019/310. With the publication of this announcement, this information is now considered to be in the public domain.

 

END